Outcomes Research in Review

Remdesivir in Hospitalized Adults With Severe COVID-19: Lessons Learned From the First Randomized Trial


 

References

Applications for Clinical Practice

The discovery of an effective pharmacologic intervention for COVID-19 is of utmost urgency. While the present study was unable to answer the question of whether remdesivir is effective in improving clinical outcomes in patients with severe COVID-19, other ongoing or completed (ie, ACTT) studies will likely address this knowledge gap in the coming months. The FDA’s emergency use authorization for remdesivir provides a glimpse into this possibility.

–Katerina Oikonomou, MD, Brookdale Department of Geriatrics & Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

–Fred Ko, MD

Pages

Recommended Reading

COVID-19 fears tied to dangerous drop in child vaccinations
Journal of Clinical Outcomes Management
Consider COVID-19–associated multisystem hyperinflammatory syndrome
Journal of Clinical Outcomes Management
Hazard pay included in new COVID-19 relief bill
Journal of Clinical Outcomes Management
Dermatologic changes with COVID-19: What we know and don’t know
Journal of Clinical Outcomes Management
COVID-19 in kids: Severe illness most common in infants, teens
Journal of Clinical Outcomes Management
Antibody testing suggests COVID-19 cases are being missed
Journal of Clinical Outcomes Management
Vitamin D: A low-hanging fruit in COVID-19?
Journal of Clinical Outcomes Management
Maskomania: Masks and COVID-19
Journal of Clinical Outcomes Management
Inflammation, thrombosis biomarkers tied to COVID-19 deaths
Journal of Clinical Outcomes Management
Today’s top news highlights: Risks & benefits of universal masking, prostate cancer rising
Journal of Clinical Outcomes Management